Global Lyme Disease Diagnostics Market By Diagnostic Test (Direct Detection Test (Culture, Polymerase Chain Reaction (PCR) Testing, Antigen Detection) Indirect Detection Test (ELISA, Western Blot, Immunofluorescence (IFA), Immunoblot) Cerebrospinal Fluid Tests, Brain Imaging (Magnetic Resonance Imaging, SPECT Imaging, PET Imaging) Neuropsychological Testing, Others); By Stages (Early localized Lyme, Early disseminated Lyme, Late disseminated Lyme); By Sample (Blood, Cerebrospinal Fluid (CSF), Urine, Serum, Others); By End User (Hospitals and Clinics, Specialty Clinics, Clinical Laboratories); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2023 – 2031